Subcutaneous nivolumab (NIVO SC) vs intravenous nivolumab (NIVO IV) in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Pharmacokinetics (PK), efficacy, and safety results from CheckMate 67T.

Authors :: George, Saby
Bourlon, Maria Teresa
Chacon, Matias Rodrigo
Cutuli, Hernan
Lopez Chuken, Yamil Alonso
Zurawski, Bogdan
Mota, Jose Mauricio
Magri, Ignacio
Burotto, Mauricio
Luz, Murilo
De Menezes, Juliana
Yanez Ruiz, Eduardo Patricio
Maruzzo, Marco
Bracarda, Sergio
Prusty, Subhransu
Rathod, Dhanrajsinh
Vezina, Heather
Yu, Zhuoxin
Zhao, Yue
Albiges, Laurence
Source :: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, pLBA360-LBA360, 6p
Publication Year :: 2024

Full Text Access

Tools